Day: November 14, 2025

FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular and Cortical Bone Indices, Highlighted at NAMS and ASBMR Next-Generation EB613 Remains on Track for Phase 1 Initiation in Late 2025 Pre-Clinical Data for Oral OXM in Obesity and Oral GLP-2 in Short Bowel Syndrome in Collaboration with OPKO Presented at ENDO2025 and ESPEN JERUSALEM, Nov. 14, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended September 30, 2025. “Our achievements this quarter are testament to Entera’s leadership...

ST. LOUIS, Nov. 14, 2025 (GLOBE NEWSWIRE) — The Marketing Alliance, Inc. (OTC: MAAL) (“TMA” or the “Company”), announced its financial results today for its fiscal 2026 second quarter ended September 30, 2025. Q2 2026 Financial Key Items (all comparisons to the prior year quarter)Revenues from operations were $4,668,836 compared to $4,983,950, a decrease of over 6% which was almost entirely in the construction business Operating income from continuing operations of $149,507 compared to $486,639 in the prior year quarter Net income was $263,407 or $0.04 per share in the quarter compared to $401,511 or $0.05 per share in the prior year quarter During the quarter the Company repurchased 166,146 shares, and subsequent to the end of quarter the Company repurchased an additional 50,000 shares. Repurchases under the program may be made...

Notice of Plan to Voluntary Delist from Nasdaq and Deregister its Common Stock LOS ANGELES, Nov. 14, 2025 (GLOBE NEWSWIRE) — Taitron Components Incorporated (NASDAQ:TAIT) announces the Company will voluntarily delist its common stock from The Nasdaq Stock Market (“Nasdaq”) and, based upon ownership of its shares by fewer than 300 holders of record, deregister its common stock under the Securities Exchange Act of 1934 and suspend its public reporting obligations. Our Board of Directors concluded that the costs of maintaining the Nasdaq listing and remaining a public reporting company, including costs of compliance, the demands on management time and the Company resources required to maintain its listed and registered status, outweigh the benefits to the Company and its stockholders of continued Nasdaq listing and SEC reporting. The...

Third Quarter Net Sales and Adjusted EBITDA Exceeded Guidance Driven by 44% OEM GrowthGross Margin Expanded 710 Basis Points Year-over-YearRecent Public Offerings and Debt Restructuring Significantly Improve Financial PositionGuides to Fourth Quarter Net Sales of Approximately $13.0 Million Third Quarter 2025 Financial Highlights (All comparisons made are against the prior-year period)Net sales were $16.0 million, compared to $12.7 million, up 25.5%. OEM net sales were $10.7 million, compared to $7.4 million, up 44.3% Gross Margin was 29.7%, compared to 22.6%, up 710 basis points. Net Loss was $(11.1) million, compared to $(6.8) million. Adjusted EBITDA was $(2.1) million, compared to $(5.5) million.RENO, Nev., Nov. 14, 2025 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI),...

–   Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment regarding the study design of a Phase 3 program for VP-315 in basal cell carcinoma; Company presented new data on VP-315 at the recent Society for Immunotherapy of Cancer conference – – Received positive feedback from European Medicines Agency that supports a Marketing Authorization Application filing for YCANTH for molluscum without need for additional Phase 3 studies – – Received $10 million cash milestone payment for approval of YCANTH for molluscum in Japan – – Conference call scheduled for Monday, November 17, 2025, at 8:30 am ET – WEST CHESTER, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”)...

DALLAS, Nov. 14, 2025 (GLOBE NEWSWIRE) — Strive, Inc. (Nasdaq: ASST) (“Strive” or the “Company”), the first Bitcoin treasury company amplified exclusively with perpetual preferred equity, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights:Consummated the reverse acquisition of Asset Entities Inc. and concurrently raised $762.6 million through PIPE financing transaction and warrant exercises through September 30, 2025, with the opportunity to raise an additional $736.6 million through exercise of remaining warrants. Announced the entry into an agreement and plan of merger for the acquisition of Semler Scientific, Inc. (“Semler”) in an all-stock transaction that would result in Semler being a wholly owned subsidiary of Strive, subject to the satisfaction...

MIDLAND, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) — Mawson Infrastructure Group Inc. (NASDAQ: MIGI) (“Mawson” or the “Company”), a U.S.-based technology company that designs, builds, and operates next-generation digital infrastructure platforms providing services to the artificial intelligence (AI), high-performance computing (HPC), and digital assets (including Bitcoin mining), and other intensive compute applications market sectors, announced today its financial and operational results for the three and nine months ended September 30, 2025. Kaliste Saloom, Interim CEO of Mawson, said, “Our third quarter results clearly demonstrate Mawson’s ongoing commitment to growth and our resilience. With significant improvements in revenue, gross profit, and net income, we are making real progress toward sustained profitability. The successful...

FREDERICK, Md., Nov. 14, 2025 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® (BIT™) platform, today announced financial results for the quarter ended September 30, 2025, and provided an update on strategic initiatives designed to drive long-term growth. Q3 2025 Highlights:Revenue Growth: Revenues of $2.0 million reflecting a 95% sequential increase over Q2 2025, driven primarily by higher equipment purchases and continued strength in our recurring BIT™ Solution sales. Strong Gross Margins: Gross profit margin remained healthy at 61% in Q3, underscoring the efficiency of operations and the value of the Company’s technology. Operational Efficiencies: Reduced selling, research, and...

– FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway – ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the third quarter of 2025. Corporate Highlights from 3Q 2025Announced second partner order for FemBloc in Europe Announced FDA IDE approval to continue enrollment in final phase of the FINALE pivotal trial for FemBloc Announced a definitive agreement for the issuance of $12 million in secured convertible notes and accompanying warrants for total potential funding of $58 million, if all warrants are...